BMS-986016

DRUG3 trials

Conditions

GlioblastomaHematologic NeoplasmsMicrosatellite Stable Colorectal CancerMicrosatellite Unstable Colorectal CancerMismatch Repair Deficient Colorectal CancerMismatch Repair Proficient Colorectal Cancer

Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

CompletedNCT02061761

Bristol-Myers SquibbHematologic Neoplasms

Start: 2014-03-13End: 2022-02-16Updated: 2023-03-24

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

CompletedNCT03493932

National Institute of Neurological Disorders and Stroke (NINDS)Glioblastoma

Start: 2018-09-24End: 2023-06-27Updated: 2024-07-24

Phase 2

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

CompletedNCT02060188

Bristol-Myers SquibbMicrosatellite Stable Colorectal Cancer, Microsatellite Unstable Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer +1

Start: 2014-03-12End: 2024-10-22Updated: 2025-11-06

Blood Advances2025-03-033 citations

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study

Journal for ImmunoTherapy of Cancer2024-05-0136 citations

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.

Journal of Clinical Oncology2024-01-207 citations

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Journal of Clinical Oncology2023-06-015 citations

Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

Journal of Clinical Oncology2022-06-0133 citations

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.

Journal of Clinical Oncology2021-01-2021 citations

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis

JNCI Cancer Spectrum2020-12-0720 citations

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).

2020-08-3123 citations

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Journal of Clinical Oncology2020-02-0160 citations

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.

Journal of Clinical Oncology2019-05-2016 citations

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Journal of Clinical Oncology2019-01-2939 citations

Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142

Cancer Research2018-07-018 citations

Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.

Journal of Clinical Oncology2018-02-0165 citations

Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

Journal of Clinical Oncology2018-02-0161 citations

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

2017-07-192091 citations

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

Journal of Clinical Oncology2017-05-2026 citations

Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

Journal of Clinical Oncology2017-05-209 citations

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Journal of Clinical Oncology2017-02-0170 citations

2 more papers not shown

BMS-986016

Sponsors

Conditions

Phase 1

Phase 2

Related Papers